Occurrence and characteristics of hospitalizations during first-line chemotherapy among individuals with metastatic colorectal cancer.

被引：0
|
作者：
Fisch, Michael Jordan
Grabner, Michael
Mytelka, Daniel S.
Raval, Amit D.
Bowman, Lee
Kern, David M.
Churchill, Collin
Singer, Joseph
Wetmore, Stewart
Barron, John
Eleff, Michael
机构：
[1] AIM Specialty Hlth, Chicago, IL USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] Anthem Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.691
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
691
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer
    Fisch, Michael J.
    Grabner, Michael
    Mytelka, Daniel S.
    Raval, Amit D.
    Bowman, Lee
    Kern, David M.
    Churchill, Collin
    Singer, Joseph
    Wetmore, Stewart
    Barron, John
    Eleff, Michael
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 1535 - 1541
  • [2] Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy
    Maddalena, C.
    Ponsiglione, A.
    Camera, L.
    Santarpia, L.
    Pasanisi, F.
    Bruzzese, D.
    Panico, C.
    Fiore, G.
    Camardella, S.
    Caramia, T.
    Farinaro, A.
    De Placido, S.
    Carlomagno, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S178 - S178
  • [3] Optimizing first-line chemotherapy for metastatic colorectal cancer
    Adams, Richard A.
    COLORECTAL CANCER, 2012, 1 (03) : 241 - 253
  • [4] Negative impact of cachexia during chemotherapy on survival as first-line chemotherapy for metastatic colorectal cancer
    Nozawa, Kazuki
    Masuishi, Toshiki
    Kumanishi, Ryosuke
    Nakazawa, Taiko
    Ogata, Takatsugu
    Matsubara, Yuki
    Kato, Kyoko
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Andoh, Masashi
    Tajika, Masahiro
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [5] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [6] Use of VEGF expression to predict for first-line treatment chemotherapy regimen in metastatic colorectal cancer.
    Ozkan, Metin
    Berk, Veli
    Deniz, Kemal
    Karaca, Halit
    Inanc, Mevlude
    Bozkurt, Oktay
    Duran, Ayse Ocak
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Place of first-line palliative chemotherapy in patients with metastatic colorectal cancer
    Hebbar, M
    REVUE DE MEDECINE INTERNE, 1997, 18 : S364 - S367
  • [8] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [9] Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer
    Puthillath, Ajithkumar
    Dunn, Kelli Bullard
    Rajput, Ashwani
    Smith, Judy
    Yang, Gary
    Wilding, Gregory E.
    Tan, Wei
    Gupta, Bhavna
    Fakih, Marwan G.
    CLINICAL COLORECTAL CANCER, 2007, 6 (10) : 710 - 715
  • [10] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Aparicio, Jorge
    Fernandez-Martos, Carlos
    Vicent, Jose M.
    Maestu, Inmaculada
    Llorca, Cristina
    Busquier, Isabel
    Campos, Jan M.
    Perez-Enguix, Daniel
    Balcells, Miquel
    CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 263 - 267
12345